Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Seer, Inc. (SEER:NASDAQ), powered by AI.
Seer, Inc. is currently trading at $1.70. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Seer, Inc. on Alpha Lenz.
Seer, Inc.'s P/E ratio is -1.2.
“Seer, Inc. trades at a P/E of -1.2 (undervalued) with modest ROE of -23.9%. 3Y revenue CAGR of 29.7% highlights clear growth momentum.”
Ask for details →Seer Inc. operates as a biotechnology company renowned for its expertise in developing innovative solutions for protein analysis. The core purpose of Seer is to advance scientific understanding by providing high-throughput and scalable tools to decode the proteome—the entire complement of proteins expressed by a cell, tissue, or organism. Seer’s Proteograph Product Suite significantly enhances biological research by enabling a detailed examination of protein dynamics, aiding in the development of personalized medicine and fostering breakthroughs in disease diagnostics and therapy. This cutting-edge technology is pivotal in the healthcare and pharmaceuticals sectors, where understanding proteomic profiles can lead to improved therapeutic outcomes and clinical insights. Founded to bridge the gap between genomics and proteomics, Seer Inc. plays a critical role in empowering researchers and clinicians to uncover new biomolecular insights, thereby expanding the capabilities of precision medicine. The company's contributions to the life sciences market are not only significant for scientific advancement but also for the commercialization of research into practical healthcare applications.
“Seer, Inc. trades at a P/E of -1.2 (undervalued) with modest ROE of -23.9%. 3Y revenue CAGR of 29.7% highlights clear growth momentum.”
Ask for details →